Stockysis — AI-Powered Stock News & Sentiment Analysis

UBS Maintains Buy on Kura Oncology, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 62.6%

Neg 62.6% Neu 0% Pos 0%

UBS analyst David Dai maintains Kura Oncology (NASDAQ:KURA) with a Buy and lowers the price target from $16 to $15.

Comments

No comments yet. Be the first!